Allocure is poised to be the first company to develop viable cell therapies for the effective treatment of many serious and debilitating medical conditions. AlloCure’s cell therapies represent a novel and proprietary class of biological therapeutics that will change the way a number of serious illnesses are treated. AlloCure’s most advanced therapies target acute kidney injury (AKI), kidney transplantation and multi organ failure. AlloCure’s Phase I Clinical Trial for AKI will begin in July of 2008. AlloCure is dedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure’s unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt lake City Utah and Hamburg Germany.

Amorcyte is a biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose.  This is the first prospective stem cell trial in AMI ever conducted that has established a statistically significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry, to provide Amorcyte with a pharmaceutical grade cGMP manufactured product that can be distributed commercially.

We are a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic, acute heart damage, and peripheral vascular disease. Our lead product candidate is MyoCell®, an innovative clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The core technology used in MyoCell has been the subject of human clinical trials conducted over the last six years involving 95 enrollees and 76 treated patients.

Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.